JP2010531890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531890A5 JP2010531890A5 JP2010515068A JP2010515068A JP2010531890A5 JP 2010531890 A5 JP2010531890 A5 JP 2010531890A5 JP 2010515068 A JP2010515068 A JP 2010515068A JP 2010515068 A JP2010515068 A JP 2010515068A JP 2010531890 A5 JP2010531890 A5 JP 2010531890A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- amino acid
- modified antibody
- modified
- kabat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000006467 substitution reaction Methods 0.000 claims 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 6
- 239000004473 Threonine Substances 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Chemical group 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000007485 viral shedding Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94627107P | 2007-06-26 | 2007-06-26 | |
| US95326007P | 2007-08-01 | 2007-08-01 | |
| US5492708P | 2008-05-21 | 2008-05-21 | |
| PCT/US2008/068155 WO2009003019A1 (en) | 2007-06-26 | 2008-06-25 | Methods of treating rsv infections and related conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531890A JP2010531890A (ja) | 2010-09-30 |
| JP2010531890A5 true JP2010531890A5 (enExample) | 2011-08-11 |
Family
ID=40186020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515068A Withdrawn JP2010531890A (ja) | 2007-06-26 | 2008-06-25 | Ｒｓｖ感染症及び関連する症状の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110008329A1 (enExample) |
| EP (1) | EP2069400A4 (enExample) |
| JP (1) | JP2010531890A (enExample) |
| KR (1) | KR20100049568A (enExample) |
| CN (1) | CN101687919A (enExample) |
| AU (1) | AU2008268362A1 (enExample) |
| CA (1) | CA2688667A1 (enExample) |
| WO (1) | WO2009003019A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| CN104119438A (zh) * | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| BR112012031638B1 (pt) * | 2010-07-09 | 2021-01-12 | Janssen Vaccines & Prevention B.V. | anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado |
| CN103048450B (zh) * | 2011-10-13 | 2015-09-30 | 苏州药明康德新药开发股份有限公司 | 高通量的rsv蛋白含量的定量检测法及其检测试剂盒 |
| US10011660B2 (en) | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| CN103204943B (zh) * | 2013-03-20 | 2014-07-23 | 中国科学院武汉病毒研究所 | 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途 |
| ES2795727T3 (es) * | 2014-01-15 | 2020-11-24 | Medimmune Llc | Anticuerpos específicos del vrs y partes funcionales de los mismos |
| EP3105250B1 (en) * | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| CL2015002153A1 (es) * | 2015-07-31 | 2016-01-29 | Pontificia Universidad Católica De Chile | Uso de los marcadores moleculares il-3,il33 e il-12p40 para caracterizar la severidad de infecciones respiratorias por virus respiratorio sincicial y metapneumovirus humano |
| KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
| EP3735421A4 (en) | 2018-01-05 | 2021-09-22 | Corvidia Therapeutics, Inc. | METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION |
| JP7842564B2 (ja) * | 2018-09-21 | 2026-04-08 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 粘液を透過するのを制限するための合成結合剤 |
| JP7634545B2 (ja) * | 2020-01-29 | 2025-02-21 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | ｐＨ感応性ＦＣ変異体 |
| WO2021202463A1 (en) * | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| EP1553975B8 (en) * | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| GB0324368D0 (en) * | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR20080025174A (ko) * | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
-
2008
- 2008-06-25 US US12/600,292 patent/US20110008329A1/en not_active Abandoned
- 2008-06-25 JP JP2010515068A patent/JP2010531890A/ja not_active Withdrawn
- 2008-06-25 CA CA002688667A patent/CA2688667A1/en not_active Abandoned
- 2008-06-25 AU AU2008268362A patent/AU2008268362A1/en not_active Abandoned
- 2008-06-25 EP EP08780984A patent/EP2069400A4/en not_active Withdrawn
- 2008-06-25 KR KR1020107001846A patent/KR20100049568A/ko not_active Withdrawn
- 2008-06-25 WO PCT/US2008/068155 patent/WO2009003019A1/en not_active Ceased
- 2008-06-25 CN CN200880022270A patent/CN101687919A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531890A5 (enExample) | ||
| JP6875302B2 (ja) | 抗ｋｉｔ抗体及びその使用 | |
| US20170281769A1 (en) | STABLE ANTI-IL-4Ra FORMULATION | |
| JP2023134490A (ja) | リンパ球における阻害経路の中和 | |
| FI3625259T3 (fi) | Anti-sirp-alfa vasta-aineet | |
| JP2019527194A5 (enExample) | ||
| JP2022531242A5 (enExample) | ||
| IL304089A (en) | Anti-kit antibodies and their uses | |
| JP2022512905A5 (enExample) | ||
| CA3212025A1 (en) | Bispecific pd-1 and tigit binding proteins and uses therof | |
| KR102597053B1 (ko) | 항-bcma 항체 및 그 용도 | |
| JP2023508202A5 (enExample) | ||
| IL323100A (en) | Antibodies against stem cell factor (SCF) and thymic lymphopoietin (TSLP) and bispecific constructs | |
| JP2023539107A5 (enExample) | ||
| JP7533330B2 (ja) | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 | |
| CN117136070A (zh) | 抗-kit抗体及其用途 | |
| JP2024535851A (ja) | Ｄ３結合分子及びその使用 | |
| RU2010102089A (ru) | Способы лечения инфекций рсв и ассоциированных состояний | |
| KR20250044334A (ko) | 항-kit 항체 제형 및 방법 | |
| JP2025514858A5 (enExample) | ||
| RU2021115554A (ru) | Новые молекулы антагонистических анти-tnfr2-антител | |
| RU2021119682A (ru) | Антитела против клаудина и их применение | |
| HK40014256B (zh) | 抗SIRPα抗体及其使用方法 |